Radioligand therapy and the isotope problem

14 October 2026

Delivering radiation to a tumor through an injected medicine involves a supply chain that begins well before a patient reaches hospital. Nuclear facilities produce the radioactive material, specialist manufacturers turn it into a drug, and delivery teams work to a timetable set partly by radioactive decay.

Two established treatments from Swiss pharma major Novartis (NOVN: VX), Pluvicto (lutetium Lu 177 vipivotide tetraxetan) and Lutathera (lutetium Lu 177 dotatate), use lutetium-177 to carry radiation to selected cancer cells. Their growing use has brought the infrastructure behind these medicines into closer view.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Company News Directory



Companies featured in this story

More ones to watch >






Company Spotlight



More Features in Pharmaceutical